Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study on Hepatitis C, including details about the study's purpose, inclusion and exclusion criteria, and the previous version number. The new version introduces a new revision number and mentions Hepatitis C, but lacks the detailed information previously provided.SummaryDifference11%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check111 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.